Am J Transplant, Volume 22, Suppl 3 Archives - Page 148 of 190 - ATC Abstracts

2022 American Transplant Congress
Pancreatic Islets Engineered with Thrombomodulin Show Enhanced Engraftment in an Intraportal Transplantation Model by Mitigating Instant Blood-Mediated Inflammatory Reactions
A. Turan¹, L. Zhang², M. Tarique², V. Ulker², E. Yolcu³, H. Shirwan³
¹Molecular Microbiology and Immunology, University of Missouri at Columbia, Columbia, MO, ²Department of Child Health, University of Missouri at Columbia, Columbia, MO, ³Child Health and Molecular Microbiology and Immunology, University of Missouri at Columbia, Columbia, MO
*Purpose: IBMIR is a major culprit of early islet loss post-transplant. Thrombomodulin (TM) is an anti-coagulant and cofactor of activated Protein C (APC) that perpetuates…
2022 American Transplant Congress
Role of Mitochondrial Transplantation in Enhancing Liver Regeneration Following Partial Hepatectomy
G. Lamanilao¹, C. Watkins¹, C. Kuscu¹, C. Kuscu¹, J. Eason², A. Bajwa¹
¹Transplant Research Institute, James D. Eason Transplant Institute, Department of Surgery, The University of Tennessee Health Science Center, Memphis, TN, ²University of Tennessee/Methodist Transplant Institute, Memphis, TN
*Purpose: Therapeutic strategies that accelerate the rate of liver regeneration following partial hepatectomy (PH) should be developed to reduce occurrences of small for size syndrome…
2022 American Transplant Congress
Implementing Clinical Decision Support Tools for Immunosuppressant Drug-Drug Interactions to Prevent Graft Failure
A. Yishak¹, S. Ledan², S. Mukherjee³, C. Chen², A. Ayoola², T. Kim², A. Olenik², K. Mullican², A. Henje², N. Lorence², L. Beckman²
¹MAPMG, Mc Lean, VA, ²Kaiser Permanente, Silver Spring, MD, ³MAPMG, Rockville, MA
*Purpose: Immunosuppressant drug-drug interactions can result in immunosuppressant toxicity or subtherapeutic levels causing rejection. If not identified and managed appropriately, these interactions may result in…
2022 American Transplant Congress
Normothermic Ex Vivo Pancreas Perfusion for the Preservation of Porcine Pancreas Grafts
C. Parmentier, S. Ray, L. Mazilescu, M. Kawamura, T. Goto, Y. Noguchi, B. Arulratnam, S. Ganesh, M. Selzner, T. Reichman
Multi-Organ Transplant Department, University Health Network - Toronto General Hospital, Toronto, ON, Canada
*Purpose: The purpose of this study was to develop a stable porcine model for normothermic ex-vivo pancreas perfusion (NEVPP) for the preservation of grafts with…
2022 American Transplant Congress
Sirolimus Use Is Associated With An Improved Immune Response To Covid-19 Vaccination In Kidney Transplant Recipients
G. B. Perkins¹, M. Tunbridge², T. Salehi², C. Chai¹, C. M. Hope¹, P. Garcia-Valtanen¹, J. J. Singer³, P. R. Hurtado², S. C. Barry¹, B. Grubor-Bauk¹, P. Hissaria², S. J. Chadban³, P. Coates¹
¹University of Adelaide, Adelaide, Australia, ²Royal Adelaide Hospital, Adelaide, Australia, ³Royal Prince Alfred Hospital, Sydney, Australia
*Purpose: Kidney transplant recipients (KTRs) are highly vulnerable to severe COVID-19, however are poorly protected by vaccination. Additional vaccine doses have achieved limited improvements in…
2022 American Transplant Congress
Exploring Individual Optimal Immunosuppression Management According to the Oncological Risk in Liver Transplanted Patients with Hepatocellular Carcinoma
K. Sasakik¹, S. Kimura², D. Soma³, K. Tomiyama⁴, M. Matthew⁴, M. Fruscione², C. Kubal³, D. Kwon⁵
¹Stanford University, Palo Alto, CA, ²Massachusetts General Hospital, Belmont, MA, ³Indiana University, Indianapolis, IN, ⁴University of Rochester, Rochester, NY, ⁵Cleveland Clinic, Cleveland, OH
*Purpose: Post-Liver transplant (LT) immunosuppression management is the only modifiable factor to prevent hepatocellular carcinoma (HCC) recurrence; however, the impact of immunosuppression on the HCC…
2022 American Transplant Congress
A2/A2B to B Kidney Transplantation Outcomes: A Single-Center 5 Year Experience
A. El Chediak, S. Shawar, M. Fallahzadeh, I. Feurer, S. Rega, J. L. Triozzi, D. Shaffer
Vanderbilt University Medical Center, Nashville, TN
*Purpose: The new kidney allocation system (KAS) instituted in 2014 allowed organ procurement organizations to allocate A2/A2B to B candidates preferentially was meant to improve…
2022 American Transplant Congress
Case-Control Study of Belatacept as Maintenance Immunosuppression in Kidney Transplant Recipients Living with HIV
M. Tucker, C. Foppiano Palacios, E. Cohen, S. Virmani, P. Trubin, L. A-Barakat, M. M. Azar, M. Malinis
Yale School of Medicine, New Haven, CT
*Purpose: Belatacept has been increasingly used in kidney transplant recipients (KTR) as a calcineurin-inhibitor (CNI) sparing agent. There are little data on belatacept use in…
2022 American Transplant Congress
Demographic Characteristics of VCA Candidates and Recipients in the U.S.
J. Wainright¹, L. Cartwright¹, A. Henderson¹, W. Cherikh¹, S. Booker¹, D. Klassen²
¹Research, UNOS, Richmond, VA, ²Office of the Chief Medical Officer, UNOS, Richmond, VA
*Purpose: As with other fields of transplantation, it is important to understand the populations VCA transplantation is serving.*Methods: This study used OPTN VCA waiting list…
2022 American Transplant Congress
HLA-DRB1 and DQB1 Amino Acid Mismatches as Determinants of Kidney Allograft Failure
L. Gragert¹, K. P. McCullough², G. L. Wager³, R. Urbanowicz⁴, R. M. Merion², M. Kamoun⁴
¹Tulane Cancer Center, Tulane University, New Orleans, LA, ²Arbor Research Collaborative for Health, Ann Arbor, MI, ³Tulane University, New Orleans, LA, ⁴University of Pennsylvania, Philadelphia, PA
*Purpose: It was previously reported that HLA-DRB1 amino acid (AA) mismatches (MMs) at peptide-binding pockets of this molecule account for significant incremental risk of kidney…